Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2017/6218129 http://scihub22266oqcxt.onion/10.1155/2017/6218129 C5585574!5585574!28912972     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Nephrol 2017 ; 2017 (ä): ä Nephropedia Template TP {{tp|p=28912972|t=2017. Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study |pdf=|usr=}}{{28912972}} gab.com Text Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study JO: Int J Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=28912972 #FOAvip Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year and evaluated its effect on radius BMD. Seventeen patients were treated with denosumab 60?mg every 6 months, and 20 patients were not treated with denosumab (control group). At seven days, the mean corrected calcium level decreased from 9.2 ± 0.5?mg to 8.5 ± 0.5?mg (P < 0.01), and mean serum phosphorus decreased from 5.0 ± 1.3?mg/dl to 4.2 ± 0.9?mg/dl (P < 0.01). At 1 month, the corrected calcium and serum phosphorus levels were 9.2 ± 0.9?mg/dl and 4.0 ± 1.1?mg/dl, respectively. At 1 year, BMD increased by 2.6%??± 4.4% in the denosumab group and decreased by 4.5%??± 7.7% in the control group (P < 0.001). In our observational study, denosumab therapy represents an effective treatment for male dialysis patients with low BMD. Twit Text FOAVip Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study ????Int J Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=28912972 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28912972 #FOAvip English Wikipedia <ref>{{Cite pmid|28912972}}</ref> Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study #MMPMID28912972 Takami H; Washio K; Gotoh H Int J Nephrol 2017[]; 2017 (ä): ä PMID28912972show ga Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year and evaluated its effect on radius BMD. Seventeen patients were treated with denosumab 60?mg every 6 months, and 20 patients were not treated with denosumab (control group). At seven days, the mean corrected calcium level decreased from 9.2 ± 0.5?mg to 8.5 ± 0.5?mg (P < 0.01), and mean serum phosphorus decreased from 5.0 ± 1.3?mg/dl to 4.2 ± 0.9?mg/dl (P < 0.01). At 1 month, the corrected calcium and serum phosphorus levels were 9.2 ± 0.9?mg/dl and 4.0 ± 1.1?mg/dl, respectively. At 1 year, BMD increased by 2.6%??± 4.4% in the denosumab group and decreased by 4.5%??± 7.7% in the control group (P < 0.001). In our observational study, denosumab therapy represents an effective treatment for male dialysis patients with low BMD. äDenosumab for Male Hemodialysis Patients with Low Bone Mineral Density(epmc).pdf DeepDyve Pubget Overpricing